EGFR and non-small cell lung carcinoma: Since TKI therapy has demonstrated a high response rate for EGFR mutation carriers in NSCLC, many previous studies intended to improve the survival of BMs patients from NSCLC using targeted agents in addition to conventional therapy [11, 12, 14, 17–20].